While semaglutide activates only the GLP-1 receptor, tirzepatide is a dual GIP and GLP-1 receptor agonist

The lawsuits filed by people affected by GLP-1 medications focus on several serious gastrointestinal injuries: Gastroparesis (stomach paralysis) , a condition where the stomach loses its ability to properly move food into the small intestine, causing severe nausea, vomiting, malnutrition, and requiring long-term dietary changes or feeding tubes Ileus , a temporary but serious condition where intestinal motility stops, causing severe pain, bloating, inability to pass gas or stool, and sometimes requiring hospitalization Intestinal obstruction , including mechanical blockages and pseudo-obstruction where the intestines stop functioning without a physical blockage Severe and persistent nausea and vomiting , often requiring emergency room visits, IV fluids, and anti-nausea medications Cyclic vomiting syndrome , characterized by repeated episodes of severe vomiting with no apparent cause Malnutrition and severe weight loss , resulting from the inability to eat or digest food properly Dehydration and electrolyte imbalances , caused by persistent vomiting and inability to keep fluids down Many of these conditions have required hospitalization, feeding tubes, surgical interventions, and permanent dietary restrictions

Consulting with a healthcare professional can help tailor the carnivore diet to meet your specific health needs
210,211 The weight loss effects from GLP-1 RA treatment may reverse these changes and alter the pharmacokinetics of co-administered lipophilic drugs by decreasing the Vd (Figure 3)
Peptide molecular weight is the total mass of a peptide, measured in Daltons (Da)
Compatibility: Works synergistically with Vitamin C, Alpha Arbutin, Niacinamide, and Tranexamic Acid for multi-mechanism pigment control